New Jersey Innovation Institute (NJII) announced the sale of its subsidiary, BioCentriq Inc., to GC corp. for $73 million. BioCentriq manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.
Read more
NJII announces partnership with McKinsey & Company in the launch of a new center to advance operations and manufacturing excellence in cell and gene therapy (CGT).
Read more
CaroGen Corporation partners with BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trial. Learn more.
Read more
Applications for VentureLink’s BioFoundry Incubator will be open on June 15th to Cell and Gene Therapy startup founders until August 1st! This 14-week program will run from September to December.
Read more
FOR IMMEDIATE RELEASE: Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA’s Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT …
Read more
If your start-up company has developed a biological product and is planning to file an investigational new drug (IND) application with the FDA or register the product with another federal agency, and you don’t have …
Read more
The New Jersey Innovation Institute (NJII) and Choose New Jersey will be hosting a virtual ribbon cutting, tour and panel discussions to mark the opening of BioCentriq™ on Thursday, October 29 at 2:30pm. RSVP to …
Read more
A research report published just yesterday by Allied Market research affirms that the global viral vectors and plasmid DNA manufacturing market generated $918.37 million in 2019, and is projected to reach $4.97 billion by 2027, …
Read more
The New Jersey Innovation Institute’s Biopharma Division, which includes BioCentriq, its cell and gene therapy development and manufacturing center, has welcomed Beth Thompson-Webb to its advisory committee. Thompson-Webb has more than two decades of experience in life sciences …
Read more
Dr. Haro Hartounian is senior vice president and general manager of the Biopharma Division of the New Jersey Innovation Institute (NJII). The division, founded in 2015, includes a state-of-the-art cell and gene therapy development center …
Read more
NJII announces that qualification and validation of its clinical manufacturing facility for cell and gene therapies is underway, and the name of the center will be BioCentriq. May 4, 2020: Newark, N.J. – Today the …
Read more
The New Jersey Innovation Institute’s Biopharma Division welcomed Kevin D. Belfield to its advisory committee. The committee is made up of executives from leading pharmaceutical and biotech organizations, and Dr. Belfield — a renowned scientist …
Read more